3. Umbruch 4.4..2005 - Online Pot

Cannabinoids in neurodegeneration and neuroprotection 109
178 Polman CH, Uitdehaag. Br Med J 2000) Drug treatment of multiple sclerosis. Br Med J 321:
490–494
179 Hafler DA (2004) Multiple sclerosis. J Clin Invest 113: 788–794
180 Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions
correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169–180
181 Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat
Med 6: 67–70
182 Matute C, Alberdi E, Domercq M, Pérez-Cerda F, Pérez-Samartin A, Sánchez-Gómez MV (2001)
The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends
Neurosci 24: 224–230
183 Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95: 165–174
184 Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A,
Thompson AJ, Giovannoni G et al. (2003) Cannabinoids inhibit neurodegeneration in models of
multiple sclerosis. Brain 126: 2191–2202
185 Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A (2003) Thompson A. Cannabinoids for
treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre
randomised placebo-controlled trial. Lancet 362: 1517–1526
186 Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989) ∆ 9 -Tetrahydrocannabinol: a
novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23: 73–81
187 Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T (1994) Suppression of
experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28:
209–214
188 Cabranes A, Venderova K, de Lago E, Fezza F, Valenti M, Sánchez A, García-Merino A, Ramos
JA, Di Marzo V, Fernández-Ruiz J (2005) Decreased endocannabinoid levels in the brain and
beneficial effects of certain endocannabinoid uptake inhibitors in a rat model of multiple sclerosis:
involvement of vanilloid TRPV1 receptors. Neurobiol Dis; in press
189 Arévalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C (2003) Therapeutic action of
cannabinoids in a murine model of multiple sclerosis. J Neurosci 23: 2511–2516
190 Croxford JL, Miller SD (2003) Immunoregulation of a viral model of multiple sclerosis using the
synthetic cannabinoid R+WIN55,212. J Clin Invest 111: 1231–1240
191 Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, Fernández-Ruiz J
(2001) Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental
allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41: 195–202
192 Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME (2004) Amyotrophic lateral
sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph
Lateral Scler Other Motor Neuron Disord 5: 33–39
193 Chou SM (1997) Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old
disease. J Formos Med Assoc 96: 488–498
194 Maier CM, Chan PH (2002) Role of superoxide dismutases in oxidative damage and neurodegenerative
disorders. Neuroscientist 8: 323–334
195 Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N (2004) Endocannabinoids accumulate
in spinal cord of SOD1 transgenic mice. J Neurochem 89: 1555–1557